Merker H J, Heger W, Sames K, Stürje H, Neubert D
Institut für Toxikologie und Embryopharmakologie, Freie Universität Berlin, Germany.
Arch Toxicol. 1988 Jan;61(3):165-79. doi: 10.1007/BF00316631.
The response of pregnant marmosets (Callithrix jacchus) to the thalidomide derivative EM 12 was evaluated. EM 12 was selected for these studies because it is more active than thalidomide and is much more stable for hydrolysis. Skeletal gross structural abnormalities were observed when EM 12 was given to marmosets for 3-7 days during the period between days 49 and 60 post ovulation. Using the treatment schedule finally adapted in our laboratory, i.e. treatment during days 51-57 post ovulation, doses of 5 (or 10) mg EM 12/kg body wt induced the typical limb abnormalities known from man with an 80-100% certainty. In some animals we could observe the typical pattern of abnormalities even with doses as low as 1 mg EM 12/kg body wt. Abnormalities of the skeleton induced during this sensitive period are described. None of these (except some bifurcations of ribs) were seen in any of the ten litters (23 fetuses) serving as controls during the period of the study.
对怀孕狨猴(绢毛猴)对沙利度胺衍生物EM 12的反应进行了评估。选择EM 12进行这些研究是因为它比沙利度胺更具活性,并且在水解方面更稳定。在排卵后第49至60天期间,将EM 12给予狨猴3至7天,观察到骨骼大体结构异常。使用最终在我们实验室采用的治疗方案,即在排卵后第51至57天进行治疗,5(或10)mg EM 12/kg体重的剂量可导致人类已知的典型肢体异常,确定性为80-100%。在一些动物中,即使剂量低至1 mg EM 12/kg体重,我们也能观察到典型的异常模式。描述了在此敏感期诱导的骨骼异常。在研究期间作为对照的十窝(23只胎儿)中,均未观察到这些异常(除了一些肋骨分叉)。